NewAmsterdam Pharma’s Successful Obicetrapib Phase 3 Trial
Company Announcements

NewAmsterdam Pharma’s Successful Obicetrapib Phase 3 Trial

NewAmsterdam Pharma Company (NAMS) has provided an announcement.

NewAmsterdam Pharma Company N.V. reported positive outcomes from its Phase 3 BROOKLYN clinical trial for the drug obicetrapib, which significantly reduced LDL-C levels in patients with familial hypercholesterolemia on lipid-lowering therapy. The sustained benefits over a year, alongside safety results comparable to placebo, set the stage for an upcoming presentation at a medical conference and publication in a medical journal. The company’s forward-looking statements emphasize its strategic plans, regulatory milestones, and commercialization efforts for obicetrapib.

For an in-depth examination of NAMS stock, go to TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskNewAmsterdam Pharma Reports Strong Q3 and Trial Progress
TipRanks Auto-Generated NewsdeskNewamsterdam Pharma Faces Compliance Cost Surge as Emerging Growth Status Ends
TheFlyNewAmsterdam Pharma reports Q3 EPS (18c), consensus (50c)
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App